Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | SLC2A1 | P11166 | 3/20 | 0.47 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.47 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3790721 | 0.87 | NPC1 (0.61) | SMN1; SMN2NPC1RAB9AHSD17B10MEN1 | |
| SCHEMBL12204383 | 0.85 | NQO1 (0.54) | SMN1; SMN2MEN1KMT2APSMB1PSMB5 | |
| SCHEMBL9771540 | 0.84 | SMN1; SMN2 (0.49) | SMN1; SMN2NPC1RAB9AHSD17B10MEN1 | |
| SCHEMBL11398112 | 0.84 | LTA4H (0.61) | SLC2A1PSMB1PSMB5LTA4H | |
| SCHEMBL12204110 | 0.83 | KDM4E (0.56) | SMN1; SMN2 | |
| SCHEMBL6907235 | 0.83 | NR5A1 (0.62) | SMN1; SMN2NPC1RAB9AHSD17B10DRD2 | |
| SCHEMBL5018762 | 0.83 | MEN1 (0.59) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL6336026 | 0.83 | PSMB1 (0.54) | MEN1KMT2APSMB1PSMB5LTA4H | |
| SCHEMBL12204132 | 0.82 | EBP (0.52) | MEN1KMT2ADRD3LTA4HKCNH2 | |
| SCHEMBL12204130 | 0.81 | HRH3 (0.57) | MEN1KMT2ALTA4HKCNH2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8034949-B2 | Pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-10-11 | — | — | US | disclosed |
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167440-A1 | Novel pyrrolidine compound and a process for preparing the same | CNR1, CNR2, OPRD1 | SMN1; SMN2 4282/4885NPC1 1806/4885RAB9A 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.